EFFECTIVENESS OF GRANULOCYTE TRANSFUSIONS

粒细胞输注的有效性

• 批准号: 6161502
• 负责人: S F LEITMAN
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6161502
• 关键词: antibiotics; aplastic anemia; bacterial disease; clinical research; clinical trials; granulocyte; human subject; human therapy evaluation; leukocyte transfusion; microorganism disease chemotherapy; mycosis

The results of clinical trials to treat neutropenic adults with bacterial or fungal infections are controversial. Some studies have found that granulocyte transfusions are effective in treating bacterial infections but several other have not. While granulocyte transfusions have been effective in treating fungal infections in neutropenic animal models, they have not been effective in treating humans. The ineffectiveness of granulocyte transfusions is likely due in part to the limited quantity of granulocytes that can be collected. Recently, it has been shown that the number of granulocytes collected can be increased two to five-fold by giving donors granulocyte colon-stimulating factor (G-CSF). G-CSF mobilized granulocyte transfusions may be effective in treating bacterial and fungal infections in neutropenic adults. The purpose of this study is to determine if severely neutropenic aplastic anemia patients with bacterial or fungal infections benefit from granulocyte transfusions. Eligible patients will be randomly assigned to either receive conventional antimicrobial therapy or G-CSF mobilized granulocyte transfusions plus conventional antimicrobial therapy. The response of their infection to the treatments as well as their survival will be monitored.

用细菌治疗成人中性粒细胞减少症的临床试验结果 或真菌感染是有争议的。一些研究发现 粒细胞输注可有效治疗细菌感染 但其他几个人还没有。虽然粒细胞输注已 它们可有效治疗中性粒细胞减少动物模型中的真菌感染 尚未有效治疗人类。的无效性 粒细胞输注可能部分是由于粒细胞数量有限 可以收集的粒细胞。最近，有研究表明， 收集的粒细胞数量可以增加两到五倍 给予捐赠者粒细胞结肠刺激因子（G-CSF）。粒细胞集落刺激因子 动员粒细胞输注可能有效治疗细菌性 和中性粒细胞减少成人的真菌感染。本研究的目的是 确定严重中性粒细胞减少性再生障碍性贫血患者是否患有 细菌或真菌感染可受益于粒细胞输注。 符合条件的患者将被随机分配接受常规治疗 抗菌治疗或 G-CSF 动员粒细胞输注加 常规抗菌治疗。他们的感染反应 治疗及其生存情况将受到监测。